About Invictus Oncology
Invictus Oncology is a Healthcare company based in Delhi (India) founded in 2011 by Raghunath Mashelkar. Chemotherapeutics conjugated with antibodies are developed for cancer treatment. Invictus Oncology has raised $6.99 million across 7 funding rounds from investors including Aarin Capital, Navam Capital and Sabre Partners India. Invictus Oncology was last valued at $16.54 million in October 2016. Its Indian entity Invictus Oncology Private Limited reported revenue of ₹2.86 Cr. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.
Company details
Invictus Oncology was founded in 2011 in Delhi, India, within the biotechnology sector focused on oncology. Antibody-drug conjugates and platinum-based chemotherapeutics are engineered using structure-activity relationships for targeted delivery to tumors. The product pipeline addresses lung, testicular, colorectal, and childhood cancers, with operations centered on developing treatments for tumor-specific applications.
- Headquarters Delhi, India
- Founders Raghunath Mashelkar
- Stage Minicorn
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website invictusoncology.com
- Social LinkedIn
- Legal Name Invictus Oncology Private Limited
- Date of Incorporation 11 Apr, 2011
- Jurisdiction Delhi, India
- Annual Revenue₹2.86 Cr
FY 2025 · +20% YoY
- Net Loss-₹5.6 Lakh
FY 2025 · -2% margin
- EBITDA₹8 Lakh
FY 2025 · 3% margin
- Total Equity Funding$6.99M (USD)
in 7 rounds
- Latest Funding Round$552.86K (USD), Series A
Oct 2016
- InvestorsAarin Capital
& 8 more
Associated legal entities of Invictus Oncology
Invictus Oncology operates through Invictus Oncology Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Invictus Oncology Private Limited CIN U24232DL2011PTC217394 | Active | 11 Apr 2011 | Delhi, Delhi | ₹2.9 Cr | 38 | 4 | View details |
Funding Insights of Invictus Oncology
Invictus Oncology has successfully raised a total of $6.99M across 7 strategic funding rounds. The most recent funding activity was a Series A round of $552.86 thousand completed in October 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $6.99M
- Total Rounds 7
- Last Round Series A — $552,861
- First Round $89,838
(Jul 2012)
- Investors Count 9
All 7 funding rounds of Invictus Oncology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2016 | $552,861 | Series A | $16.54M | Navam Capital | |
| Jun 2016 | $516,387 | Series A | $14.68M | Aarin Capital | |
| Apr 2016 | Series A | – | Sabre Partners India | – | |
| Aug 2015 | $2.26M | Series A | $••••• | Aarin Capital, Navam Capital | |
| May 2014 | $1.7M | Series A | $••••• | Aarin Capital | |
| Feb 2013 | $1.96M | Series A | $••••• | Navam Capital, Aarin Capital | |
| Jul 2012 | $89,838 | Grant | – | – |
| Date | Valuation | Stage |
|---|---|---|
| Oct 2016 | $16.54M | •••••••• |
| Jun 2016 | $14.68M | •••••••• |
| Aug 2015 | $••••• | •••••••• |
| May 2014 | $••••• | •••••••• |
| Feb 2013 | $••••• | •••••••• |
Full valuation and stage history of Invictus Oncology
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $16.54M (Oct 2016). 9 investors in total: 6 institutional and 3 angel.
Investors in Invictus Oncology
Invictus Oncology has secured backing from 9 investors, including angel, venture fund, and institutional investors. Prominent investors backing the company include Aarin Capital, Navam Capital and Sabre Partners India.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment in engineering-driven deep-tech and science ventures in India. | 2008 | navamcapital.com | Kolkata, India | |
Venture funding in technology-intensive businesses within healthcare, education, and India-centric markets. | 2012 | aarincapital.com | Bengaluru, India | |
Private equity investments in financial services, fintech, healthcare, and healthtech sectors in India. | 2002 | sabre-partners.com | Mumbai, India | |
Venture capital is directed toward fintech and tech companies. | consiliumventures.com | London, United Kingdom | ||
Delivers comprehensive healthcare investment and management services. | springhealthcare.org | Zug, Switzerland | ||
Biotechnology research, guidelines, and funding by the Government of India. | 1986 | dbtindia.gov.in | Delhi, India | |
SL Sharad Lunia | Angel investor and entrepreneur, focused on tech startups in India. | unknown_c4c289b0c49a4d608 | ||
MN Mukund Narasimhan | unknown_8db7ae66617748998 | |||
RN Ratan N Tata | Chairman Emeritus of Tata Sons, iconic industrialist, and active angel investor | unknown_eaeb4094a8c44648a |
Investor details for Invictus Oncology
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Invictus Oncology Private Limited (Invictus Oncology)
Invictus Oncology Private Limited is the primary company behind Invictus Oncology. The board of Invictus Oncology Private Limited currently have 4 directors; the longest-serving is Rajeev Mantri, appointed in 2011. 3 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Rajeev Mantri DIN 01895901 | Nominee Director | 11 Apr 2011 | 15 yrs 7 mo | Invictus Oncology Private Limited |
| Shiladitya Sengupta DIN 01837274 | Director | 11 Apr 2011 | 15 yrs 7 mo | Invictus Oncology Private Limited |
| Raghunath Anant Mashelkar DIN 00074119 | Director | 04 Feb 2013 | 13 yrs 9 mo | Invictus Oncology Private Limited |
| Jasmin Rambhai Patel DIN 06396028 | Nominee Director | 04 Feb 2013 | 13 yrs 9 mo | Invictus Oncology Private Limited |
People of Invictus Oncology
1 people are tracked at Invictus Oncology (1 in leadership).
| Name | Role | Group |
|---|---|---|
| Co-Founder | Leadership |
Complete people profiles for Invictus Oncology
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Invictus Oncology
Figures of Invictus Oncology Private Limited, the primary company behind Invictus Oncology, for FY 2025. Revenue was ₹2.86 Cr (+20% year on year). Net loss was -₹5.6 Lakh (-2% margin). EBITDA was ₹8 Lakh (3% margin). Revenue has grown at a compounded annual rate of +44% over three years and +63% over five years.
- ₹2.86 CrRevenue · FY 2025 · +20% YoY
- -₹5.6 LakhNet loss · -2% margin
- ₹8 LakhEBITDA · 3% margin
- ₹2.06 CrPaid-up capital
- 38Employees (provident fund records)
- +44%Revenue CAGR, 3 years
- +63%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Invictus Oncology Private Limited are on its company page.
Detailed financial statements for Invictus Oncology
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Invictus Oncology
4 dated milestones of Invictus Oncology across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Invictus Oncology is founded.
- Funding First funding round of $90K.
- Milestone Reaches Minicorn status.
- Funding Latest funding round, Series A, of $553K.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Invictus Oncology
Complete news archive for Invictus Oncology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Invictus Oncology
Invictus Oncology was founded in 2011 and raised its 1st funding round 1 year after it was founded.
Invictus Oncology is headquartered in Delhi, India. It is registered at Delhi, Delhi, India.
Invictus Oncology is a funded company, having raised a total of $6.99M across 7 funding rounds to date. The company's 1st funding round was a Grant of $89.84K, raised on Jul 2012.
The primary company behind Invictus Oncology, Invictus Oncology Private Limited, reported revenue of ₹2.86 Cr for FY 2025, up 20% year on year.
Invictus Oncology was founded in 2011 in Delhi, India, within the biotechnology sector focused on oncology. Antibody-drug conjugates and platinum-based chemotherapeutics are engineered using structure-activity relationships for targeted delivery to tumors. The product pipeline addresses lung, testicular, colorectal, and childhood cancers, with operations centered on developing treatments for tumor-specific applications.
Invictus Oncology has 9 investors. Key investors include Aarin Capital, Navam Capital, Sabre Partners India, Department of Biotechnology, and Sharad Lunia.
The valuation of Invictus Oncology is $16.54M as of Oct 2016.
Invictus Oncology operates through Invictus Oncology Private Limited.
The legal entities of Invictus Oncology currently have 4 directors, including Raghunath Anant Mashelkar, Rajeev Mantri, Shiladitya Sengupta and others.